Neumifil - Pneumagen
Alternative Names: HEX-17; NeumifilTMLatest Information Update: 26 Jun 2026
At a glance
- Originator Pneumagen
- Class Anti-infectives; Antivirals; Proteins
- Mechanism of Action Epithelial cell modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Influenza virus infections
- Phase I Respiratory tract infections
- Preclinical COVID 2019 infections; Respiratory syncytial virus infections; Rhinovirus infections
Most Recent Events
- 23 Jun 2026 NorthLinks Bio plans a phase IIb trial for Respiratory tract infections
- 03 Jul 2024 Pharmacodynamics data from the preclinical trials in influenza virus, respiratory syncytial virus, coronavirus and rhinovirus released by Pneumagen
- 03 Jul 2024 Preclinical development in Respiratory-syncytial-virus-infections is ongoing in United Kingdom (Intranasal, Spray) .